BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 34349242)

  • 1. Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer.
    Qiao S; Lu W; Glorieux C; Li J; Zeng P; Meng N; Zhang H; Wen S; Huang P
    Oncogene; 2021 Sep; 40(39):5880-5892. PubMed ID: 34349242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of oxidative phosphorylation and IDH2 sensitizes colorectal cancer to a naphthalimide derivative and mitoxantrone.
    Ge C; Wang Y; Feng Y; Wang S; Zhang K; Xu X; Zhang Z; Zhao Y; Wang Y; Gao L; Dai F; Xie S; Wang C
    Cancer Lett; 2021 Oct; 519():30-45. PubMed ID: 34166768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression.
    He X; Wu N; Li R; Zhang H; Zhao Y; Nie Y; Wu J
    Cell Oncol (Dordr); 2023 Feb; 46(1):145-164. PubMed ID: 36401762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.
    Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P
    J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.
    Li JJ; Yu T; Zeng P; Tian J; Liu P; Qiao S; Wen S; Hu Y; Liu Q; Lu W; Zhang H; Huang P
    Nat Commun; 2024 Apr; 15(1):3445. PubMed ID: 38658533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH2 deficiency accelerates skin pigmentation in mice via enhancing melanogenesis.
    Park JH; Ku HJ; Lee JH; Park JW
    Redox Biol; 2018 Jul; 17():16-24. PubMed ID: 29660504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of IDH2 Accelerates Age-related Hearing Loss in Male Mice.
    White K; Kim MJ; Han C; Park HJ; Ding D; Boyd K; Walker L; Linser P; Meneses Z; Slade C; Hirst J; Santostefano K; Terada N; Miyakawa T; Tanokura M; Salvi R; Someya S
    Sci Rep; 2018 Mar; 8(1):5039. PubMed ID: 29567975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Mitochondrial IDH2 Enhances Antitumor Activity of Cisplatin in Lung Cancer via ROS-Mediated Mechanism.
    Li H; Li JJ; Lu W; Yang J; Xia Y; Huang P
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SUMOylation enhances the activity of IDH2 under oxidative stress.
    Yu Y; Chen Y; Liu K; Cheng J; Tu J
    Biochem Biophys Res Commun; 2020 Nov; 532(4):591-597. PubMed ID: 32900482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive oxygen species-mediated senescence is accelerated by inhibiting Cdk2 in Idh2-deficient conditions.
    Chae U; Park JW; Lee SR; Lee HJ; Lee HS; Lee DS
    Aging (Albany NY); 2019 Sep; 11(17):7242-7256. PubMed ID: 31503005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2.
    Chen X; Yang P; Qiao Y; Ye F; Wang Z; Xu M; Han X; Song L; Wu Y; Ou WB
    Sci Rep; 2022 Nov; 12(1):18830. PubMed ID: 36335201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idh2 deficiency accelerates renal dysfunction in aged mice.
    Lee SJ; Cha H; Lee S; Kim H; Ku HJ; Kim SH; Park JH; Lee JH; Park KM; Park JW
    Biochem Biophys Res Commun; 2017 Nov; 493(1):34-39. PubMed ID: 28928092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH2 protects against nonalcoholic steatohepatitis by alleviating dyslipidemia regulated by oxidative stress.
    Gong F; Gao L; Ding T
    Biochem Biophys Res Commun; 2019 Jun; 514(3):593-600. PubMed ID: 31064654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH2 deficiency impairs mitochondrial function in endothelial cells and endothelium-dependent vasomotor function.
    Park JB; Nagar H; Choi S; Jung SB; Kim HW; Kang SK; Lee JW; Lee JH; Park JW; Irani K; Jeon BH; Song HJ; Kim CS
    Free Radic Biol Med; 2016 May; 94():36-46. PubMed ID: 26898144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isocitrate dehydrogenase 2 deficiency aggravates prolonged high-fat diet intake-induced hypertension.
    Noh MR; Kong MJ; Han SJ; Kim JI; Park KM
    Redox Biol; 2020 Jul; 34():101548. PubMed ID: 32388270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of the mitochondria-targeted antioxidant MitoQ in mitochondrial-ROS induced sensorineural hearing loss caused by Idh2 deficiency.
    Kim YR; Baek JI; Kim SH; Kim MA; Lee B; Ryu N; Kim KH; Choi DG; Kim HM; Murphy MP; Macpherson G; Choo YS; Bok J; Lee KY; Park JW; Kim UK
    Redox Biol; 2019 Jan; 20():544-555. PubMed ID: 30508699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial NADP
    Han SJ; Jang HS; Noh MR; Kim J; Kong MJ; Kim JI; Park JW; Park KM
    J Am Soc Nephrol; 2017 Apr; 28(4):1200-1215. PubMed ID: 27821630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRT5 promotes IDH2 desuccinylation and G6PD deglutarylation to enhance cellular antioxidant defense.
    Zhou L; Wang F; Sun R; Chen X; Zhang M; Xu Q; Wang Y; Wang S; Xiong Y; Guan KL; Yang P; Yu H; Ye D
    EMBO Rep; 2016 Jun; 17(6):811-22. PubMed ID: 27113762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.